Payment overview · 2025
General Payments
$443.73
24 reported records · 10 companies
Healthcare provider profile · identity verified
Tyrel K Somers, MD
Allopathic & Osteopathic Physicians|Family Medicine · RUSSELL, KS · NPI 1174879936
Verified facts
What the public records show
CMS Open Payments records show Tyrel K Somers, MD received $443.73 in general payments during 2025 across 24 reported records.
Sumitomo Pharma America, Inc. accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 407 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $110.63 | 24.9% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $63.42 | 14.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.85 | 13.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.25 | 11.3% | 3 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $48.90 | 11.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.70 | 6.7% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $25.88 | 5.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.02 | 4.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.59 | 3.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.49 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $443.73 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $110.63 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $63.42 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $50.25 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $48.90 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $25.88 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 407 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
71 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
407 | 47 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1116 | 197 |
| Atorvastatin Calcium | Atorvastatin Calcium | 707 | 132 |
| Lisinopril | Lisinopril | 564 | 113 |
| Potassium Chloride | Potassium Chloride | 487 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 469 | 84 |
| Gabapentin | Gabapentin | 411 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 411 | 72 |
| Eliquis | Apixaban | 407 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 385 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 374 | 64 |
| Simvastatin | Simvastatin | 372 | 70 |
| Furosemide | Furosemide | 366 | 72 |
| Tramadol Hcl | Tramadol Hcl | 340 | 72 |
| Losartan Potassium | Losartan Potassium | 338 | 72 |
| Metformin Hcl | Metformin Hcl | 319 | 65 |
| Warfarin Sodium | Warfarin Sodium | 313 | 25 |
| Omeprazole | Omeprazole | 300 | 59 |
| Trazodone Hcl | Trazodone Hcl | 232 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 220 | 36 |
| Oxycodone Hcl | Oxycodone Hcl | 219 | 23 |
| Lorazepam | Lorazepam | 218 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 215 | 50 |
| Montelukast Sodium | Montelukast Sodium | 199 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 40 |
| Allopurinol | Allopurinol | 193 | 31 |
| Alprazolam | Alprazolam | 171 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 168 | 34 |
| Donepezil Hcl | Donepezil Hcl | 166 | 22 |
| Prednisone | Prednisone | 162 | 69 |
| Pregabalin | Pregabalin | 162 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 160 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 157 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 151 | 23 |
| Sertraline Hcl | Sertraline Hcl | 148 | 23 |
| Mirtazapine | Mirtazapine | 145 | 21 |
| Buspirone Hcl | Buspirone Hcl | 142 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 140 | 21 |
| Spironolactone | Spironolactone | 137 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 22 |
| Meloxicam | Meloxicam | 125 | 29 |
| Bumetanide | Bumetanide | 122 | 18 |
| Fentanyl | Fentanyl | 121 | 19 |
| Carvedilol | Carvedilol | 117 | 29 |
| Famotidine | Famotidine | 108 | 16 |
| Clonazepam | Clonazepam | 101 | 13 |
| Celecoxib | Celecoxib | 99 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 27 |
| Fluconazole | Fluconazole | 94 | 34 |
| Ventolin Hfa | Albuterol Sulfate | 94 | 26 |
| Myrbetriq | Mirabegron | 93 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 89 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 85 | suppressed |
| Aripiprazole | Aripiprazole | 83 | suppressed |
| Chlorthalidone | Chlorthalidone | 83 | 21 |
| Levetiracetam | Levetiracetam | 82 | suppressed |
| Memantine Hcl | Memantine Hcl | 82 | 12 |
| Diazepam | Diazepam | 81 | 16 |
| Propranolol Hcl | Propranolol Hcl | 81 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 12 |
| Nystatin | Nystatin | 76 | 35 |
| Metformin Hcl Er | Metformin Hcl | 75 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 72 | 13 |
| Synthroid | Levothyroxine Sodium | 71 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 70 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 17 |
| Glimepiride | Glimepiride | 67 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 19 |
| Finasteride | Finasteride | 65 | suppressed |
| Cephalexin | Cephalexin | 64 | 45 |
| Ozempic | Semaglutide | 64 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 35 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 61 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 14 |
| Estradiol | Estradiol | 58 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | suppressed |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Temazepam | Temazepam | 55 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 53 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 51 | suppressed |
| Olanzapine | Olanzapine | 51 | suppressed |
| Jardiance | Empagliflozin | 50 | suppressed |
| Movantik | Naloxegol Oxalate | 50 | suppressed |
| Topiramate | Topiramate | 50 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 49 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 49 | 38 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 47 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 31 |
| Methocarbamol | Methocarbamol | 46 | suppressed |
| Baclofen | Baclofen | 45 | suppressed |
| Gemtesa | Vibegron | 45 | suppressed |
| Primidone | Primidone | 45 | suppressed |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Ondansetron Odt | Ondansetron | 44 | 22 |
| Risperidone | Risperidone | 44 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 43 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Lovastatin | Lovastatin | 42 | suppressed |
| Premarin | Estrogens, Conjugated | 42 | suppressed |
| Sucralfate | Sucralfate | 41 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 40 | 39 |
| Cefdinir | Cefdinir | 40 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 39 | suppressed |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 26 |
| Xtampza Er | Oxycodone Myristate | 39 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | suppressed |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 29 |
| Loxapine | Loxapine Succinate | 36 | suppressed |
| Glipizide | Glipizide | 35 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 34 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 28 |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | 13 |
| Ziprasidone Hcl | Ziprasidone Hcl | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Latanoprost | Latanoprost | 28 | suppressed |
| Methadone Hcl | Methadone Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 22 |
| Naproxen | Naproxen | 26 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Admelog Solostar | Insulin Lispro | 24 | suppressed |
| Budesonide | Budesonide | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Buprenorphine | Buprenorphine | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Clarithromycin | Clarithromycin | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ursodiol | Ursodiol | 14 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Clozapine | Clozapine | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | 11 |
| Guanfacine Hcl Er | Guanfacine Hcl | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Dapsone | Dapsone | 11 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Humira Pen | Adalimumab | 11 | suppressed |
| Linezolid | Linezolid | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Oxaprozin | Oxaprozin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $443.73 · 24 records | Sumitomo Pharma America, Inc. | AIRSUPRA, DALVANCE, ELIQUIS, EVENITY, FARXIGA, GEMTESA, LEQVIO, Omnipod, QULIPTA, REXULTI, SMARTVEST, TEFLARO, UBRELVY, VOQUEZNA, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error